Reviewing Alnylam Pharmaceuticals Inc. (ALNY)’s and OHR Pharmaceutical Inc. (NASDAQ:OHRP)’s results

Since Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) and OHR Pharmaceutical Inc. (NASDAQ:OHRP) are part of the Biotechnology industry, they are influenced by compare. The influences particularly affect the dividends, analyst recommendations, profitability, risk, earnings and valuation, institutional ownership of both companies.

Valuation and Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Alnylam Pharmaceuticals Inc. 91.80M 94.57 692.28M -6.96 0.00
OHR Pharmaceutical Inc. N/A 0.00 13.24M -0.22 0.00

Table 1 demonstrates Alnylam Pharmaceuticals Inc. and OHR Pharmaceutical Inc.’s top-line revenue, earnings per share and valuation.


Table 2 has Alnylam Pharmaceuticals Inc. and OHR Pharmaceutical Inc.’s return on equity, net margins and return on assets.

Net Margins Return on Equity Return on Assets
Alnylam Pharmaceuticals Inc. -754.12% -41.8% -37.5%
OHR Pharmaceutical Inc. 0.00% -62.7% -54.6%

Volatility and Risk

Alnylam Pharmaceuticals Inc.’s volatility measures that it’s 150.00% more volatile than Standard and Poor’s 500 due to its 2.5 beta. In other hand, OHR Pharmaceutical Inc. has beta of -0.03 which is 103.00% less volatile than Standard and Poor’s 500.


Alnylam Pharmaceuticals Inc.’s Current Ratio is 11 while its Quick Ratio is 11. On the competitive side is, OHR Pharmaceutical Inc. which has a 5.5 Current Ratio and a 5.5 Quick Ratio. Alnylam Pharmaceuticals Inc. is better positioned to pay off short and long-term obligations compared to OHR Pharmaceutical Inc.

Analyst Ratings

Alnylam Pharmaceuticals Inc. and OHR Pharmaceutical Inc. Recommendations and Ratings are available in the next table.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Alnylam Pharmaceuticals Inc. 1 3 6 2.60
OHR Pharmaceutical Inc. 0 0 0 0.00

$120.11 is Alnylam Pharmaceuticals Inc.’s consensus target price while its potential upside is 46.91%.

Institutional & Insider Ownership

Alnylam Pharmaceuticals Inc. and OHR Pharmaceutical Inc. has shares held by institutional investors as follows: 90.5% and 14.6%. About 0.3% of Alnylam Pharmaceuticals Inc.’s share are held by insiders. On the other hand, insiders held about 8.91% of OHR Pharmaceutical Inc.’s shares.


Here are the Week, Month, Quarter, Half Year, Year and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Alnylam Pharmaceuticals Inc. -5.51% 0.84% -26.44% -23.35% -40.43% -39.64%
OHR Pharmaceutical Inc. -5.33% -32.38% -25.58% -34.41% -90.21% -92.37%

For the past year Alnylam Pharmaceuticals Inc. was less bearish than OHR Pharmaceutical Inc.


Alnylam Pharmaceuticals Inc. beats OHR Pharmaceutical Inc. on 7 of the 10 factors.

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes novel therapeutics based on RNA interference. Its pipeline of investigational RNAi therapeutics is focused on genetic medicines, cardio-metabolic diseases, and hepatic infectious diseases. The companyÂ’s clinical development programs include Patisiran, which is in Phase III clinical trial for the treatment of transthyretin-mediated amyloidosis (ATTR); Fitusiran, an investigational RNAi therapeutic that is in Phase I/II clinical trial for the treatment of hemophilia and rare bleeding disorders; and Inclisiran (ALN-PCSsc), which is in Phase II clinical trial for hypercholesterolemia. Its early stage clinical programs include Givosiran that is in Phase I trial to treat acute hepatic porphyrias; ALN-CC5 for the treatment of complement-mediated diseases; ALN-GO1 to treat primary hyperoxaluria 1; ALN-TTRsc02, an investigational RNAi therapeutic targeting TTR for the treatment of various forms of ATTR amyloidosis; and ALN-HBV for the treatment of Hepatitis B virus. The company has strategic alliances and collaboration agreements primarily with Sanofi Genzyme; The Medicines Company; Monsanto Company; Takeda Pharmaceutical Company Limited; Ionis Pharmaceuticals, Inc.; The University of British Columbia; and Acuitas Therapeutics Inc.; and Arbutus Biopharma Corporation. Alnylam Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Cambridge, Massachusetts.

OHR Pharmaceutical, Inc., a pharmaceutical company, focuses on the development of novel therapeutics and delivery technologies for the treatment of ocular disease. Its lead clinical program is topical Squalamine, a small molecule anti-angiogenic drug, which could provide a non-invasive therapy to enhance vision outcomes. The company is evaluating Squalamine, which completed Phase II clinical trials for the treatment of retinal diseases, including wet-AMD, proliferative diabetic retinopathy, and retinal vein occlusion. Its preclinical pipeline of sustained release programs include sustained release formulations of small molecule and protein therapeutics for the treatment of ocular diseases, such as glaucoma, steroid induced glaucoma, ocular allergy, and retinal disease. OHR Pharmaceutical, Inc. is headquartered in New York, New York.


Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.